JNCE's logo.
Ticker Symbol: JNCE

Jounce Therapeutics Inc

$9.00 - 20-12-2024 4 p.m. ET

Exchange: NASDAQ Country: US Currency: USD Asset Type: Common Stock CIK:0001640455

Company Profile

Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients through a biomarker-driven approach. Jounce currently has multiple development stage programs ongoing while simultaneously advancing additional early-stage assets from its robust discovery engine based on its Translational Science Platform. Jounce's highest priority program, JTX-8064, is a LILRB2 (ILT4) receptor antagonist shown to reprogram immune-suppressive tumor associated macrophages to an anti-tumor state in preclinical studies. A Phase 1 clinical trial, named INNATE, for JTX-8064 as a monotherapy and in combination with JTX-4014, Jounce's internal PD-1 inhibitor, or pembrolizumab is currently enrolling patients with advanced solid tumors. Jounce's most advanced product candidate, vopratelimab, is a monoclonal antibody that binds to and activates ICOS, and is currently being studied in the SELECT Phase 2 trial. JTX-4014 is a PD-1 inhibitor intended for combination use in the INNATE and SELECT trials and with Jounce's broader pipeline. Additionally, Jounce exclusively licensed worldwide rights to JTX-1811, a monoclonal antibody targeting CCR8 and designed to selectively deplete T regulatory cells in the tumor microenvironment, to Gilead Sciences, Inc.

Sector: Manufacturing
Industry: Biological Product (except Diagnostic) Manufacturing
Standard Industrial Classification Code (SIC code): 2836
Address: 780 Memorial Dr
Website: jouncetx.com
CEO: Richard Murray
Tags:
  • Health Technology
  • Biotechnology
  • Manufacturing
  • Biological Product (except Diagnostic) Manufacturing

Pricing

Last Updated: December 31, 1969 07:00 PM EST
Previous Close: -
Change: -$0.05 ( -2.59%)
Days Range: $1.88 - $1.93
Beta: -
52wk. High: -
52wk. Low: -
Ytd. Change -2.59%
50 Day Moving Average: -
200 Day Moving Average: -
Shares Outstanding: 52635468

Valuation

Market Cap: 9.9B
PE Ratio: -
EPS (TTM): 0

Dividends

Dividend Per Share (TTM): -
Dividend Yield (TTM): 0.00%
Ex-Dividend Date: N/A